Drugs / anti-CEA-CAR-T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06013111 | Oct 2023 → Sep 2026 overdue | carcinoma | China Medical University, China | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CEA-CAR-T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06013111 ↗ |
| Modality | Cell therapy | “anti-CEA-CAR-T cell” NCT06013111 ↗ |
| Route | Intravenous | “Anti-CEA-CAR-T cell is administered as a single intravenous infusion.” NCT06013111 ↗ |